Your browser doesn't support javascript.
loading
Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
Matito, A; Escribese, M M; Longo, N; Mayorga, C; Luengo-Sánchez, O; Pérez-Gordo, M; Matheu, V; Labrador-Horrillo, M; Pascal, M; Seoane-Reula, M E.
Afiliación
  • Matito A; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spai.
  • Escribese MM; Department of Basic Medical Sciences, Faculty of Medicine, San Pablo CEU University, Madrid, Spain.
  • Longo N; Allergy Department, Hospital Universitario de Araba, Osakidetza, Vitoria, Spain.
  • Mayorga C; Allergy Research Group, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga-IBIMA, ARADyAL, Málaga, Spain.
  • Luengo-Sánchez O; Allergy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB).
  • Pérez-Gordo M; Basic Medical Science Department, Faculty of Medicine, CEU San Pablo University, ARADyAL, Madrid, Spain.
  • Matheu V; IDP and Allergy Department, Hospital Universitario de Canarias, Tenerife, Spain.
  • Labrador-Horrillo M; Allergy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB).
  • Pascal M; Immunology Department, CDB, Hospital Clínic de Barcelona; IDIBAPS, Universitat de Barcelona; ARADyAL research network, Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
  • Seoane-Reula ME; Pediatric Allergy and Immunology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain J Investig.
J Investig Allergol Clin Immunol ; 31(6): 461-470, 2021 Dec 21.
Article en En | MEDLINE | ID: mdl-33541851
ABSTRACT
The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level to >20% + 2 ng/mL within 1-4 hours after onset of the acute crisis; and (3) response of MCA symptoms to antimediator therapy. Classification of MCAS requires highly sensitive and specific methodological approaches for the assessment of clonal bone marrow mast cells at low frequencies. The Spanish Network on Mastocytosis score has been used successfully as a predictive model for selecting MCAS candidates for bone marrow studies based on a high probability of an underlying clonal mast cell disorder. In this article, we propose a diagnostic algorithm and focus on the practical evaluation and management of patients with suspected MCAS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mastocitosis / Síndrome de Activación de Mastocitos / Anafilaxia Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Investig Allergol Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mastocitosis / Síndrome de Activación de Mastocitos / Anafilaxia Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Investig Allergol Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article